The Readout Loud
296: Legal insider trading, booming biotech stocks, & the next GLP-1
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it's such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.
Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.